Search Results

Quince Therapeutics, Inc. (Nasdaq: QNCX) today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 beginning at 1:30 p.m. Eastern Time.

Quince Therapeutics, Inc. today announced the launch of a Scientific Advisory Board.

Quince Therapeutics, Inc. provided an update on the company’s development pipeline and reported financial results for the first quarter ended March 31, 2024.

Quince Therapeutics, Inc. today announced that the first patient has been dosed in the company’s Phase 3 NEAT ( N eurologic E ffects of EryDex on Subjects with A - T ) clinical trial to evaluate the neurological effects of EryDex in patients with Ataxia-Telangiectasia (A-T).

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its EryDex System for the treatment of patients with Ataxia-Telangiectasia (A-T).

Quince Therapeutics, Inc., a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will participate at two investor events taking place in San Francisco, California in January 2024.

Quince Therapeutics, Inc. today provided an update on the company’s development pipeline and reported financial results for the fourth quarter and fiscal year ended December 31, 2023.